A comparative study of panipenem/betamipron and imipenem/cilastatin in bacterial pneumonia

Kohei Hara, Yomei Hiraga, Mitsuhide Omichi, Kazuo Takebe, Mitsuo Masuda, Seiichi Murakami, Masakatsu Matsukawa, Gen Fukushi, Hisashi Nakahata, Tsukasa Yoshida, Toshiharu Ito, Masaaki Arakawa, Koichi Wada, Takashi Kawashima, Masanaga Takato, Fumihide Iwata, Naoki Osaki, Gen Takeda, Osamu Sekine, Yasutoshi SuzukiSaburo Izumi, Masataka Katsu, Akira Oishi, Shinichi Enomoto, Masaru Koyama, Kaoru Shimada, Osamu Sakai, Jingoro Shimada, Kohya Shiba, Masaki Yoshida, Hiroichi Tanimoto, Kazuo Obara, Hiroyuki Kobayashi, Shoichiro Irimajiri, Yasuo Matsuoka, Mitsuo Obana, Fumio Matsumoto, Kaoru Shimokata, Syuzo Sakai, Yoshihiro Senda, Yoshio Torii, Masashi Yamamoto, Keisuke Nishiwaki, Hiroshi Saito, Kojiro Yasunaga, Seibun Yonezu, Kouichiro Ida, Yoshihiro Ueda, Fumio Miki, Nobuhiro Narita, Masayoshi Sawaki, Keiichi Mikasa, Susumu Kishimoto, Tomiya Masuno, Takahiko Yoshimoto, Hideki Hara, Masami Ito, Naoyoshi Koujiro, Toshiyuki Ikeda, Norio Ochi, Tetsuya Ogawa, Toru Sasaki, Akemi Numamoto, Tsuyoshi Igarashi, Kiyoshi Komuta, Keiji Maeda, Eiro Tsubura, Masaru Nakagawa, Rinzo Soejima, Masaru Sumi, Toshiharu Matsushima, Makoto Kimura, Masayasu Kawanishi, Makoto Kurimura, Hideo Sasaki, Kikuo Nakano, Akimasa Ohune, Takaaki Matsui, Koutaro Ohizumi, Youichiro Ichikawa, Michiya Matsunami, Masaharu Kinoshita, Eiichi Higuchi, Keizo Matsumoto, Yoshiro Araki, Masayuki Ando, Kazuko Sakata, Atsushi Saito, Yoshiteru Shigeno, Yuei Irabu, Hiroshi Fukuhara, Osamu Zaha, Jun Inatome, Mitsuyoshi Nakashima, Keizo Yamaguchi, Mitsuo Kaku, Kazuyuki Sugawara

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

With the aim of objectively evaluating the efficacy, safety and usefulness of panipenem/betamipron (PAPM/BP) in the treatment of bacterial pneumonia, a comparative study using imipenem/cilastatin sodium (IPM/CS) as the control drug was undertaken, and the following results obtained. Either PAPM/BP or IPM/CS, in a dose of 1.0 g/1.0 g daily (in 2 divided doses), was administered for a duration of, in principle, 14 days. 1) Clinical efficacy: The efficacy rate in the judgement of the committee was 84.5% in the PAPM/BP group and 91.1% in the IPM/CS group, with no significant difference between the two groups. Judged by the physician in charge, the rate was 85.9% in the PAPM/BP group and 82.1% in the IPM/CS group, with no significant difference between the two groups. 2) Bacteriological efficacy: The eradication rate was 78.3% in the PAPM/BP group and 100% in the IPM/CS group, with no significant difference between the two groups. 3) Side effects and abnormal laboratory data: The incidence of side effects was 3.6% in the PAPM/BP group and 5.7% in the IPM/CS group. Abnormal laboratory data were found in 39.5% and 26.5% respectively, but none was serious and no significant difference was seen between the two groups. 4) Usefulness: The rate of usefulness was evaluated by the committee to be 83.1% in the PAPM/BP group and 85.7% in the IPM/CS group, with no significant difference between the two groups. Judged by the physician in charge, the rate was 84.5% in the PAPM/BP group and 83.6% in the IPM/CS group, with no significant difference between the two groups. These results confirm that the administration of PAPM/BP, 1.0 g/1.0 g daily in the treatment of bacterial pneumonia is as clinically useful as the administration of IPM/CS, 1.0 g/1.0 g daily.

Original languageEnglish
Pages (from-to)509-531
Number of pages23
JournalChemotherapy
Volume40
Issue number4
DOIs
Publication statusPublished - 1992 Apr

Keywords

  • Bacterial pneumonia
  • Comparative study
  • IPM/CS
  • PAPM/BP
  • panipenem/betamipron

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint Dive into the research topics of 'A comparative study of panipenem/betamipron and imipenem/cilastatin in bacterial pneumonia'. Together they form a unique fingerprint.

Cite this